Beyond the Vial: How Eli Lilly’s New Multi-Dose Zepbound Pen is Rewriting the Rules of Weight Loss Treatment

The global demand for GLP-1 and GIP receptor agonists—the blockbuster medications transforming obesity and diabetes management—has created unprecedented challenges for healthcare supply chains. For years, the bottleneck hasn’t just been manufacturing the drug itself, but producing the millions of single-use…






